Article
Licensed
Unlicensed
Requires Authentication
From Bench to Bedside: New Technologies for Cancer Diagnosis and Treatment
-
Published/Copyright:
May 9, 2008
According to the centre for disease control (CDC) malignant neoplasms are the second most common cause of death in the US in 2004 (1). One of the major problems is that most of the cancers are diagnosed in an advanced stage, which prohibits curative treatment. In order to circumvent these problems, we need to develop strategies that allow identification of risk patients and tumors at an early stage. In addition, it is necessary to identify prognostic and predictive biomarkers that guide patient treatment at different stages of the disease.
Published Online: 2008-05-09
Published in Print: 2008-April
You are currently not able to access this content.
You are currently not able to access this content.
Articles in the same Issue
- Editorial
- National Bioethics Committees in selected States of North Africa and the Middle East
- The Progress of Chinese Legal Protection in Genetic Resources
- DNA Profiling Bill 2007: Parliament of the Republic of India, New Delhi
- Development of the Pharma and Biotech Industry in India with Focus on R&D Activities
- From Bench to Bedside: New Technologies for Cancer Diagnosis and Treatment
- The Brain on the Stand? Interactions between Neuroscience, Ethics and Law
Articles in the same Issue
- Editorial
- National Bioethics Committees in selected States of North Africa and the Middle East
- The Progress of Chinese Legal Protection in Genetic Resources
- DNA Profiling Bill 2007: Parliament of the Republic of India, New Delhi
- Development of the Pharma and Biotech Industry in India with Focus on R&D Activities
- From Bench to Bedside: New Technologies for Cancer Diagnosis and Treatment
- The Brain on the Stand? Interactions between Neuroscience, Ethics and Law
